Validation of In Vivo Receptor Measurements Via In Vitro Radioassay: Technetium-99m-Galactosyl-Neoglycoalbumin as Prototype Model

Masatoshi Kudo, David R. Vera, Walter L. Trudeau, and Robert C. Stadalnik

Departments of Radiology and Internal Medicine, University of California, Davis, Medical Center, Sacramento, California

Hepatic binding protein (HBP) is a hepatocyte-specific receptor for serum asialoglycoproteins. The receptor also recognizes a synthetic glycoprotein that has been developed as a radiopharmaceutical, technetium-99m-galactosyl-neoglycoalbumin (99mTc-NGA). This report describes the correlation between receptor parameters measured in vivo via kinetic modeling of 99mTc-NGA and those measured by in vitro radioassay of biopsied liver tissue. Eleven patients with diffuse hepatic disease underwent percutaneous liver biopsy followed by a 99mTc-NGA functional imaging study. In vivo measurements of HBP quantity Rb and forward binding rate constant kb obtained from the kinetic analysis of 99mTc-NGA liver and blood time-activity data were compared to total receptor quantity and the HBP-99mTc-NGA association constant km as measured by Scatchard binding assay of the biopsied tissue. The correlation coefficients between in vivo and in vitro measurements were 0.73 (df=8, p=0.015) and 0.98 (df=8, p<0.01) for Rb and kb, respectively. The in vivo measurements of HBP biochemistry via kinetic analysis of the radiopharmaceutical time-activity data reflect the average concentration and affinity of the receptor. This study further substantiates the validity of 99mTc-NGA as a quantitative probe for the HBP receptor.


Receptor-binding radiopharmaceuticals (1) are recognized and bound by large molecules called receptors. These macromolecules often reside at the plasma membrane of specific tissues and, after binding by a ligand, elicit a physiologic or pharmacologic effect. Receptor-binding radiotracers exist for specific functions of the brain (2-8), myocardium (9) and liver (10). Various investigators have proposed mathematical models (9,11–16) to obtain in vivo measurements of receptor number and affinity from imaging observations with these radiopharmaceuticals. These model values could provide a quantitative index for patient diagnosis and therapeutic management. Before these radiopharmaceuticals and their kinetic models are used in the clinical setting, the validity of the kinetic analysis must be established. One step in validation is a demonstration that the model parameters representing receptor quantity and affinity correlate with independent values measured by accepted analytic techniques.

With the goal of quantitative diagnosis of hepatic disease, we have developed technetium-99m-galactosyl-neoglycoalbumin (99mTc-NGA) (17) and a complementary kinetic model (13,18). This receptor-binding radiopharmaceutical is a synthetic radioligand that is recognized by hepatic binding protein (HBP), a hepatocyte-specific receptor that binds galactose-terminated glycoproteins at the plasma membrane of hepatocytes. The resulting ligand-receptor complex is transported to lysosomes where the ligand is catabolized; the receptor is subsequently recycled to the cell surface and reused (19-20). Incorporated into our kinetic model are two parameters, [R] and kb, that conceptually represent the average concentration of HBP at the hepatocyte plasma membrane and the forward binding rate constant, respectively. The latter parameter is directly proportional to ligand-receptor affinity. Multiplication of an additional model parameter, Vb, by parameter [R] yields an estimate of total receptor quantity, Rb.

This study was designed to test the hypothesis that model parameters Rb and kb inferred from kinetic analysis of 99mTc-NGA time-activity data reflect the magnitude of tissue HBP quantity and the NGA-HBP affinity. We therefore tested the correlations of kinetic parameters Rb and kb with values of total HBP quantity and the NGA-HBP equilibrium constant measured by in vitro radioassay of hepatic tissue obtained by percutaneous biopsy immediately prior to 99mTc-NGA functional imaging.

MATERIALS AND METHODS

Patient Population

Ten patients (six males and four females; aged 29–73 yr), were imaged with 99mTc-NGA following a routine clinical percutaneous liver biopsy. The final diagnosis was based on histologic examination and included: acute hepatitis (n=2), chronic hepatitis (n=3), early primary biliary cirrhosis (n=1), alcoholic cirrhosis (n=3), and cholangiocarcinoma (n=1). The 99mTc-NGA study and liver biopsy were performed on the same day (n=6) or
within three days (n=4). Tissue for the receptor assay was placed in a polypropylene vial with a rubber-sealed screw cap (Strasttedt; Princeton, NJ) and stored at −70°C. The storage time of each sample ranged from 2 to 16 mo. The protocol was approved by the University of California, Davis Human Subjects Review Committee.

In Vivo Assay

The 99mTc-NGA preparation (17), imaging procedure (10), and data analysis (18) have been described. The NGA used in this study contained an average galactose density of 24 galactose units per human serum albumin molecule. Based on preliminary clinical data (10), we selected a scaled molar dose of 1.8 × 10−6 mole per kilogram of body weight. This dose provided sufficient receptor occupancy to yield estimates of [R]0 and k0 with high precision (13,18). Injected activity of 99mTc-NGA ranged from 4 to 6 mCi. Patients were imaged in the supine position under a large field of view gamma camera (ARC 3000; ADAC Laboratories, Milpitas, CA) fitted with a low-energy all-purpose parallel-hole collimator. Computer (DPS 33000; ADAC Laboratories, Milpitas, CA) acquisition of gamma camera data was for 30 min. Three minutes after injection 1.0 ml of venous blood was drawn. Time-activity curves for the heart and liver (the entire organ) were generated with the use of standard nuclear medicine software. The fraction of injected NGA per liter of plasma was calculated based on radioactivity assay of an aliquot of the injected dose and the 3-min blood sample.

Estimates of [R]0 and k0 were obtained by curve-fitting patient liver and blood time-activity data to a kinetic model, as detailed in a companion paper (18). Briefly, a four-compartment model of a bimolecular reaction was used to simulate the 99mTc-NGA-HBP radiopharmaceutical system. Using standard least squares techniques, the biochemical parameters of receptor concentration [R]0 and forward binding rate constant k0, as well as hepatic plasma flow F, extra-hepatic plasma volume V e, hepatic plasma volume V h, and a detector sensitivity coefficient σ, were adjusted until the simulated curves matched the heart and liver time-activity data. Total receptor quantity, R0 in vitro, was then calculated by multiplication of [R]0 by V h. Errors for each parameter were calculated via local identifiability analysis (13) and reported as the relative standard error.

In Vitro Assay

A NGA with a galactose density of 42 units per albumin molecule was prepared and labeled (choloramine-T) with iodine-125 for the Scatchard and reverse-binding assays (21). The 125I-NGA was separated from free iodine by elution with 0.9% NaCl through G-25M Sephadex (PD-10; Pharmacia, Piscataway, NJ) and assayed for protein concentration (22). Proper ligand concentrations were obtained by dilution with filtered (0.2 µm) assay buffer (pH 7.5) containing 0.33 M NaCl, 0.01 M CaCl2, and 0.03 M 4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid (HEPES).

The in vitro binding assay was carried out under the conditions outlined by Van Lenten and Ashwell (23), with modifications to accommodate our small sample size. Frozen liver biopsy tissue weighing 3.6–10.9 mg was homogenized in 150 µl of cold acetone (−20°C) using a microsomal tissue grinder-(Radnoti Glass, Monrovia, CA) that had been stored at −20°C. The homogenate consisted of 10 complete strokes and 20 rotations over 5 min. After addition of 15 ml of cold acetone, the homogenate was centrifuged (Accuspin FR; Beckman Instruments, Palo Alto, CA) at 600 G, 4°C for 15 min. The supernatant was removed and the pellet was dried by a stream of filtered air. The resulting acetone powder was reconstituted and rehomogenized in 1.2 ml of filtered assay buffer (pH 7.5) consisting of 0.33 M NaCl, 0.01 M CaCl2, and 0.03 M HEPES. After sampling, 20 µl of membrane suspension in triplicate for protein assay (22), 1.2 ml of filtered (0.45 µm) assay buffer containing 0.1% bovine serum albumin (BSA) (Sigma Chemical, St. Louis, MO) was added to the membrane suspension.

The Scatchard binding assay was performed by incubating 200 µl of membrane suspension in duplicate with 125I-NGA at one of three initial concentrations 6.4 × 10−12, 8.0 × 10−11, and 1.6 × 10−10 M for 9 hr at 37°C in polypropylene tubes (12 × 75 mm) with gentle magnetic stirring. Final assay volume was 400 µl. A blank containing 200 µl of [125I]-NGA at each initial NGA concentration and 200 µl of assay buffer was also incubated under similar conditions. The membrane suspension or blank was applied to an assembly containing a 0.45-µm filter (HVLP 013; Millipore Corp., Bedford, MA) which had been soaked for 10 min in filtered (0.45 µm) assay buffer containing 0.1% BSA. Each filter assembly was then centrifuged (High Speed Centrifuge with Model HSR-16 rotor; Savant Instruments, Farmingdale, NY) at 3600 G for 10 min. The assemblies were rinsed twice by application of assay buffer (1 ml) and centrifugation. The filters were placed in plastic 20-ml counting vials and assayed for radioactivity (20–40 keV).

Receptor concentration and affinity were calculated (see Appendix) via linear regression (24) of B/F on [B], which forms a standard Scatchard plot (25) of bound/free versus concentration bound. The equilibrium constant K, was calculated as the negative of the slope of the regression line. Errors for slopes and y-intercepts were calculated via standard methods (24). The receptor concentration within the assay tube, [R]0, was determined as the y-intercept divided by K, Receptor concentration was converted to receptor quantity via multiplication by the assay volume. Based on an approximate liver weight of 2.2% of total-body weight (26) and the amount of membrane per assay, the total amount of HBP (R0 in vitro) was determined.

A final point regarding k0 pertains to our use of 125I-NGA-42 (42 galactose units per albumin molecule) as the radioligand for the in vitro binding assays. This preparation had a higher carbohydrate density, and therefore a higher k0 (21) by a factor of 1.25, than the technetium-labeled NGA-24 employed in the imaging studies. Therefore, 125I-NGA-42 provided Scatchard plots with greater slopes, and thus measurement values of K, and [R]0 in vitro of higher precision. Use of [125I]NGA-24 would produce more scatter in the correlation plot of k0 (see Fig. 2) and would decrease the magnitude of the in vitro measurements.

The reverse-binding assay was carried out in the following manner. The 200 µl of membrane suspension were incubated in a polypropylene tube (12 × 75 mm) with 200 µl of 8.0 × 10−13 M 125I-NGA for 9 hr at 37°C. At this time, 100 µl of 5 × 10−9 mol/ml NGA (42 galactose units per human serum albumin) were added. At 1 and 15 hr after the addition of nonlabeled NGA, two 100-µl aliquots were applied to two filter assemblies and centrifuged (3200 G). The assemblies were then rinsed with assay buffer and centrifuged. The filtrates and standard were counted as described above. Reverse-binding rate constant k−s, was calculated as the negative of the slope resulting from linear regression of ln(B/F) on time, where the fraction bound FB was calculated via Equation A4 (see Appendix). The forward-binding rate constant, k0, was obtained by multiplication of K, by k−s.

The Journal of Nuclear Medicine • Vol. 32 • No. 6 • June 1991 1178
The relative standard error for $k_b$ (se($k_b$)) was calculated by quadratic addition of the relative errors for $K_a$ and $k_{vitr}$ (24).

**Reproducibility**

Reproducibility of the in vitro assay was tested by using two surgical specimens (histologically-proven) of normal and cirrhotic livers. Membrane isolation and Scatchard assays were performed 12 times for each specimen using tissue samples with sizes similar to the percutaneous specimens.

**Statistical Analysis**

This study tested two null hypotheses: (1) a linear relationship between in vivo measurements of $R_a$ via $^{99m}$Tc-NGA imaging and HBP quantity from the biopsy assay does not exist, and (2) a linear relationship between in vivo measurement of $k_b$ via $^{99m}$Tc-NGA imaging and constant $K_a$ obtained from the biopsy assay does not exist. Association was tested by calculation of the Pearson correlation coefficient following a weighted linear regression (SAS JMP; Cary, NC). The reciprocal of se($R_{in vitro}$)$^2$ or se($K_a$)$^2$ was used as the weighting factor. A confidence level of 95% was used as the criterion for significance. Statistical comparison between the mean receptor density of surgically resected normal liver and cirrhotic liver was made with the Student's $t$-test (two-tailed, unpaired) at a confidence level of 95%. Standard linear regression (24) was employed for Lowry, Scatchard, and reverse-binding assays. Mean and standard deviation were calculated for slopes and $y$-intercepts. Errors resulting from multiplication or division were assumed to propagate as the quadratic sum (24) of relative errors. Weighted linear regression was used to calculate the slope and $y$-intercept of each correlation plot.

**RESULTS**

In vitro measurements of surgical specimens detected $0.430 \pm 0.041 \mu$ mole HBP per mole of protein (mean ± s.e.m.) in the normal liver (12 samples from a single biopsy) and $0.144 \pm 0.012 \mu$ mole HBP per mole of protein in the cirrhotic liver (12 samples from a single biopsy). The difference between the means was statistically significant (p<0.001). The standard deviation of the Lowry assay was 5%. All blanks contained less than 1% of the incubated activity. Patient age, sex, weight, height, expected plasma volume (27), and hepatic plasma flow (26) are listed in Table 1.

In vitro assay and in vivo results are listed in Tables 2 and 3, respectively. Table 2 includes the amount of assayed

---

**TABLE 2**

In Vitro Binding Assay

<table>
<thead>
<tr>
<th>Study no.</th>
<th>Liver tissue (mg)</th>
<th>$K_a$ (nM$^{-1}$)</th>
<th>$k_{in vitro}$ (min$^{-1}$)</th>
<th>$k_{in vitro}$ (μM$^{-1}$ min$^{-1}$)</th>
<th>$R_{in vitro}$ (μmole)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.9</td>
<td>1.47 ± (0.63)</td>
<td>2.41 ± (0.38)</td>
<td>3.56 ± (0.73)</td>
<td>0.081 ± (0.63)</td>
</tr>
<tr>
<td>2</td>
<td>5.3</td>
<td>1.05 ± (0.47)</td>
<td>3.21 ± (0.22)</td>
<td>3.37 ± (0.51)</td>
<td>0.058 ± (0.47)</td>
</tr>
<tr>
<td>3</td>
<td>5.7</td>
<td>1.08 ± (0.37)</td>
<td>4.53 ± (0.11)</td>
<td>4.88 ± (0.72)</td>
<td>0.100 ± (0.71)</td>
</tr>
<tr>
<td>4</td>
<td>10.9</td>
<td>1.32 ± (0.37)</td>
<td>2.70 ± (0.10)</td>
<td>3.57 ± (0.38)</td>
<td>0.029 ± (0.37)</td>
</tr>
<tr>
<td>5</td>
<td>3.6</td>
<td>1.57 ± (0.45)</td>
<td>1.79 ± (0.01)</td>
<td>2.82 ± (0.47)</td>
<td>0.088 ± (0.47)</td>
</tr>
<tr>
<td>6</td>
<td>4.9</td>
<td>1.81 ± (0.36)</td>
<td>1.61 ± (0.30)</td>
<td>2.92 ± (0.46)</td>
<td>0.031 ± (0.36)</td>
</tr>
<tr>
<td>7</td>
<td>5.5</td>
<td>1.47 ± (0.62)</td>
<td>3.55 ± (0.08)</td>
<td>5.20 ± (0.62)</td>
<td>0.022 ± (0.62)</td>
</tr>
<tr>
<td>8</td>
<td>4.4</td>
<td>1.08 ± (0.44)</td>
<td>3.59 ± (0.19)</td>
<td>3.88 ± (0.48)</td>
<td>0.070 ± (0.44)</td>
</tr>
<tr>
<td>9</td>
<td>3.8</td>
<td>1.51 ± (0.69)</td>
<td>0.42 ± (1.28)</td>
<td>0.63 ± (1.45)</td>
<td>0.048 ± (0.69)</td>
</tr>
<tr>
<td>10</td>
<td>7.2</td>
<td>0.99 ± (0.77)</td>
<td>4.17 ± (0.08)</td>
<td>4.12 ± (0.78)</td>
<td>0.081 ± (0.79)</td>
</tr>
</tbody>
</table>

* Mean ± (se(p)/p).
tissue, the equilibrium association constant $K_a$, the NGAHBP forward-binding rate constant $k_b$, the reverse-binding rate constant $k_o$, and the total receptor quantity $R_0$ in vitro. The three latter values are reported with relative standard deviations. Table 3 lists the estimates and relative standard errors for parameters $[R]_o$, $k_b$, hepatic plasma flow $F$, and total plasma volume $V_p$, total receptor quantity $R_0$ in vitro, and a measure of the systematic curve-fit error, the reduced chi-square (24). Linear correlation coefficients for the Scatchard and reverse-binding assays ranged from 0.54 to 0.82 and 0.87 to 0.99, respectively.

Correlation between model parameters and the in vitro measurements is presented in Figures 1 and 2. Error bars representing 1 s.d. are included. Variables $R_0$ in vitro and $R_0$ in vivo were highly correlated ($r=0.73$, df=8, $p=0.015$). Linear regression with $R_0$ in vitro as the ordinate yielded a y-intercept and slope of $-0.007 \mu$ mole and 0.33 ± 0.13, respectively. Model parameter $k_b$ and the forward-binding rate constant as measured by in vitro binding assay were also significantly correlated ($r=0.98$, df=8, $p<0.01$). Linear regression of $k_b$ in vitro with $k_b$ in vivo yielded a y-intercept of zero and slope of $5 \times 10^2$ min$^{-1}$, respectively. We therefore rejected each null hypothesis and concluded that in vivo estimates of $R_0$ and $k_b$ reflect the magnitude of receptor quantity and ligand-receptor affinity.

DISCUSSION

Rational development of receptor-binding radiopharmaceuticals can be divided into four stages. The first is a demonstration that the mechanism of localization of the new radiotracer is receptor-mediated. This has been accomplished for several radiopharmaceuticals: $^{18}$F-DOPA (4), $^{125}$I-3-quinuclidinyl 4-iodobenzilate (QNB) (8), $^{11}$C-quinuclidinyl benzilate methiodide (MQNB) (9), $^{18}$F-spiropenidol (SP) (2,5), $^{11}$C-N-methyl-spiiperone (NMSP) (3), and $^{99m}$Tc-NGA (28,17). The second stage is a demonstration that an alteration in biodistribution reflects a change in specific physiologic state. Studies with $^{18}$F-DOPA (7), $^{125}$I-QNB (6), $^{11}$C-MQNB (9), $^{11}$C-NMSP (12), and $^{99m}$Tc-NGA (10) have demonstrated altered time-activity data for various disease and physiologic states. Neither of these early stages require a kinetic model.

The goal of the third stage is a validation of the method as an accurate measurement of receptor biochemistry. This stage involves several levels and incorporates a kinetic model of tracer localization. Kinetic models have been proposed and tested for $^{11}$C-MQNB (9), $^{18}$F-SP (11,16), $^{11}$C-NMSP (12), $^{11}$C-raclopride (14), and $^{99m}$Tc-NGA (18). This requires that simulation of the model can accurately describe the tracer's time-activity data and is used to test the plausibility of the model's structure. For example, the $^{99m}$Tc-NGA model is composed of two processes: a hemodynamic component determined by flow and volume and a biochemical component determined by a bimolecular

![Receptor Quantity](image)

**FIGURE 1.** Total receptor quantity $R_0$ correlated with the total amount of HBP as measured by in vitro assay ($r=0.73$, df=8, $p=0.015$). The correlation was determined by weighted linear regression.

<table>
<thead>
<tr>
<th>TABLE 3</th>
<th>In Vivo Assay Results*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject</td>
<td>$[R]_o$</td>
</tr>
<tr>
<td>no.</td>
<td>(\mu M)</td>
</tr>
<tr>
<td>1</td>
<td>0.789 ± (0.068)</td>
</tr>
<tr>
<td>2</td>
<td>0.672 ± (0.093)</td>
</tr>
<tr>
<td>3</td>
<td>0.866 ± (0.150)</td>
</tr>
<tr>
<td>4</td>
<td>0.849 ± (0.012)</td>
</tr>
<tr>
<td>5</td>
<td>0.803 ± (0.015)</td>
</tr>
<tr>
<td>6</td>
<td>0.362 ± (0.016)</td>
</tr>
<tr>
<td>7</td>
<td>0.270 ± (0.196)</td>
</tr>
<tr>
<td>8</td>
<td>0.402 ± (0.075)</td>
</tr>
<tr>
<td>9</td>
<td>0.426 ± (0.083)</td>
</tr>
<tr>
<td>10</td>
<td>0.697 ± (0.014)</td>
</tr>
</tbody>
</table>

* Mean ± (se/p)/p.
\dagger Total plasma volume = $V_s + V_v$.
\ddagger $R_{0_{in\,vivo}} = [R]_o V_v$. 

The Journal of Nuclear Medicine • Vol. 32 • No. 6 • June 1991
In the present study, the parameter $k_b$, which was measured in vitro, was highly correlated with the model parameter $K_a$, which when divided by $k_b$ (assumed constant by the model) equals $K_d$. Calculation of $k_b$ from in vitro assay required two separate measurements: $K_d$ from the Scatchard assay and $K_a$ from the reverse-binding assay. The combined error of both measurements produced excessively high relative errors (0.5—1.5). As a result, the correlation of $k_b$ in vitro with $k_b$ in vivo was not significant. The possibility exists that $k_b$ is not altered in diseased tissue. Therefore, the direct correlation of $99mTc$-NGA-HBP $k_b$ will require an in vitro assay of higher precision to measure the relatively small differences in $k_b$.

In conclusion, in vivo measurements of HBP biochemistry obtained via modeling of $99mTc$-NGA dynamic imaging is now shown to correlate with in vitro assays of HBP quantity and ligand affinity. This observation further substantiates the validity of in vivo measurements of HBP biochemistry. This work was supported by U.S. Public Health Service grants RO1-AM34768 and RO1-AM34706 from the National Institute of Arthritis, and U.S. Department of Energy grant DE-FG03-87ER60553.

ACKNOWLEDGMENTS

The authors thank Drs. Kenneth A. Krohn, William C. Eckelman, and Paul O. Scheibe for valuable discussions and critical reviews. We also acknowledge the excellent technical assistance of Dusan P. Hutak. This study was supported by U.S. Public Health Service grants RO1-AM34768 and RO1-AM34706 from the National Institute of Arthritis, and U.S. Department of Energy grant DE-FG03-87ER60553.
This paper was presented at the 36th Annual Meeting of The Society of Nuclear Medicine as the 1989 Berson-Yalow award.

REFERENCES


EDITORIAL

A Perspective: In Vivo Assay of Receptor-Ligand Binding

Workers in nuclear medicine have repeatedly referred to the field as depending on "function" rather than on differences between tissue densities or related properties. But what aspects of function are we measuring? Most are on a macroscopic level. Results are usually reported in comparison with a standard. For example, after ingestion of 123I-sodium iodide, thyroidal "uptake" is expressed as a percent of the ingested dose.

The exact amount of stable iodide accumulated by the thyroid is difficult to evaluate; the radiotracer administered is often "carrier-free." Intrapituitary radioiodide accumulation represents the net of multiple processes, principally the difference between uptake of radiotracer and discharge of radioiodide or iodinated products. The blood stream content of stable iodide, blood flow to the thyroid, extraction, orga
cination, storage and discharge are all occurring. Analysis of this degree of complexity is usually not attempted, although portions of the pathway can often be examined. Another way of expressing this is that: (1) data needed to provide a full analysis are usually not available and (2) a more detailed assay may have little relevance for clinical measurement.

The two papers by Vera and co-workers (1,2) provide an approach to examining events not on a macroscopic scale, but on the microscopic level. They have provided a means of analyzing the binding of a radioactive ligand to a specific receptor (hepatic binding protein or HBP). Quantitative analysis was possible, by means of imaging, blood sampling and reasonable as-

Received Dec. 3, 1990; accepted Dec. 3, 1990.
For reprints contact: Richard P. Spencer, MD, PhD, University of Connecticut Health Center, Farmington, CT 06030.

The Journal of Nuclear Medicine • Vol. 32 • No. 6 • June 1991